Sugi Predict

Sugi Predict / Compounds / SCHEMBL534889

SCHEMBL534889

SCHEMBL534889

COC(=O)c1cc(CBr)ccc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.50
▸ FOLH1 Q04609 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ CYP4F2 P78329 2/20 0.49
▸ CYP4A11 Q02928 2/20 0.49
▸ SLC6A3 Q01959 4/20 0.49
▸ GABRA1 P14867 1/20 0.47
▸ GABRG2 P18507 1/20 0.47
▸ GABRB3 P28472 1/20 0.47
▸ GABRA3 P34903 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ GAA P10253 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ EGFR P00533 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28949910 0.91 KDM4E (0.56) KDM4EFOLH1CYP1A2CYP2D6CYP2C9
SCHEMBL27348527 0.89 GABRA1 (0.48) KDM4EFOLH1CYP1A2CYP2D6CYP2C9
SCHEMBL6629659 0.88 CYP4F2 (0.49) KDM4ECYP4F2CYP4A11SLC6A3GABRA1
SCHEMBL14508877 0.86 CYP4F2 (0.48) KDM4EFOLH1CYP1A2CYP2D6CYP2C9
SCHEMBL3234150 0.86 CYP4F2 (0.62) KDM4EFOLH1CYP1A2CYP2D6CYP2C9
SCHEMBL10512148 0.85 LOXL2 (0.51) KDM4EFOLH1CYP1A2CYP2D6CYP2C9
SCHEMBL1069726 0.85 FOLH1 (0.47) FOLH1CYP4F2CYP4A11ALDH1A1MEN1
Hydrochloric Acid SCHEMBL10512036 0.84 CSNK2A1 (0.51) KDM4EFOLH1CYP1A2CYP2D6CYP2C9
SCHEMBL2568596 0.83 LMNA (0.48) KDM4EFOLH1CYP1A2CYP2D6CYP2C9
SCHEMBL30461149 0.83 FOLH1 (0.71) FOLH1ALDH1A1MEN1KMT2ALTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114814041-B Method for detecting brominated alkanes genotoxic impurities in telmisartan by adopting liquid chromatography-mass spectrometer 浙江金立源药业有限公司 2024-05-10 — — CN claimed
CN-111948862-A Nano-doped liquid crystal writing board film with light source and preparation method thereof 南京优写智能科技有限公司 2020-11-17 — — CN claimed
CN-106008356-A Preparation method for telmisartan 浙江华海药业股份有限公司 2016-10-12 — — CN claimed
CN-102557987-A Method for preparing sartan antihypertensive drug side-chain YICHANG CHANGJIANG PHARMACEUTICAL CO LTD 2012-07-11 — — CN claimed
EP-1748990-B1 PROCESS FOR THE PREPARATION OF TELMISARTAN CIPLA LTD (IN) 2008-06-25 — — EP claimed
US-20080015359-A1 Process for the Preparation of Telmisartan CIPLA LIMITED (IN) 2008-01-17 — — US claimed
EP-1748990-A1 PROCESS FOR THE PREPARATION OF TELMISARTAN Cipla Ltd. (IN) 2007-02-07 — — EP claimed
WO-2005108375-A1 PROCESS FOR THE PREPARATION OF TELMISARTAN CIPLA LIMITED (IN) 2005-11-17 — — WO claimed
US-12421273-B2 Ectonucleotidase inhibitors and methods of use thereof ANTENGENE THERAPEUTICS LIMITED (CN) 2025-09-23 — — US disclosed
CN-114814041-B Method for detecting brominated alkanes genotoxic impurities in telmisartan by adopting liquid chromatography-mass spectrometer 浙江金立源药业有限公司 2024-05-10 — — CN disclosed
US-20240132533-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF ANTENGENT THERAPEUTICS LIMITED (CN) 2024-04-25 — — US disclosed
CN-112888696-B Exonuclease inhibitors and methods of use thereof 德琪医疗有限公司 2024-04-16 — — CN disclosed
US-11858957-B2 Ectonucleotidase inhibitors and methods of use thereof ANTENGENT THERAPEUTICS LIMITED (CN) 2024-01-02 — — US disclosed
US-11858957-B2 Ectonucleotidase inhibitors and methods of use thereof ANTENGENT THERAPEUTICS LIMITED (CN) 2024-01-02 — — US disclosed
EP-0652869-A1 IMIDAZOLE ETHERS HAVING A II ANTAGONIST ACTIVITY. LUSO FARMACO INST (IT) 1995-05-17 — — EP disclosed
EP-0641329-A1 COMPOUNDS HAVING ANGIOTENSINE II ANTAGONISTIC ACTIVITY ISTITUTO LUSO FARMACO D'ITALIA S.p.A. (IT) 1995-03-08 — — EP disclosed
US-5242928-A Angiotensin II antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-09-07 — — US disclosed
EP-0556789-A2 Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1993-08-25 — — EP disclosed
CN-1058774-A PYRIDINE DERIVATIVES HAVING ANGIOTENSIN II ANTAGONISM MEIJI SEIKA CO (JP) 1992-02-19 — — CN disclosed
EP-0323841-A2 Substituted pyrrole, pyrazole and triazole angiotensin II antagonists E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132533-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF NT5E, ENTPD5, NT5C2 KDM4E 2596/4885FOLH1 106/4885CYP1A2 1394/4885
US-11858957-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 KDM4E 2596/4885FOLH1 106/4885CYP1A2 1394/4885
US-12421273-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 KDM4E 2596/4885FOLH1 106/4885CYP1A2 1394/4885
US-20080015359-A1 Process for the Preparation of Telmisartan REN, ACE, AGT KDM4E 132/4885FOLH1 907/4885CYP1A2 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.